Back

Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.

31 August 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Phenotypic approach in heart failure therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Melissa Pherai

Rotterdam (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
In-hospital initiation of Vericiguat and short-term cardiovascular function improvement in heart failure patients with worsened renal function
Professor J. She (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)
Doctor M. Pastore (Siena, IT) Doctor A. Stefanini (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Comparison of ventricular tachyarrhythmias in HF patients on dapagliflozin versus empagliflozin
Doctor P. Wilson (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan infusions for advanced heart failure: a systematic review and meta-analysis of randomized controlled trials.
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients
Doctor A. Villaschi (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotypic approach in heart failure therapy

The Event

Event poster

ESC Congress 2024

31 August 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 Inhibitor related polycythaemia: a potential severe side effect.
thumbnail
Congress Presentation
Uncoupling erythropoiesis from cardiorenal effects: SGLT2 inhibition in non-diabetic heart failure
thumbnail
Congress Presentation
Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources